Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|May 22, 2017

Janssen Defends Remicade Patents in New Lawsuit

Janssen filed a lawsuit in a US District Court in New Jersey against Samsung Bioepis, claiming the company’s new biosimilar infringed on its Remicade patents.

On May 17, 2017, Janssen, a subsidiary of Johnson & Johnson (J&J), filed a lawsuit in a district court in New Jersey against Samsung Bioepis, alleging the company’s recently approved infliximab biosimilar infringes on Janssen’s patents for Remicade (infliximab). The lawsuit seeks to halt the commercial marketing of Samsung’s biosimilar Renflexis (infliximab-abda) in the United States.

Renflexis is the second FDA-approved biosimilar for Remicade and the first Samsung Bioepis product approved for marketing in the US. Samsung told Reuters it believes the lawsuit is an attempt by Janssen to impede its Remicade biosimilar’s entry into the US market.

"We are confident we do not infringe Janssen's patents," Samsung Bioepis told Reuters. "We will take all necessary measures against Janssen's attempts to violate patient rights and deny patient access to effective, lower-cost treatment options."

Remicade is a blockbuster treatment for J&J and accounted for approximately 9.7% of the company’s 2016 revenue. J&J has said that it plans to “vigorously defend” its patents for the treatment, which is the company’s highest selling US product, accounting for nearly $5 billion in sales.

Source: United States District Court of New Jersey, Reuters 


Related to this article

The BioPharm Brief: FDA’s Fast-Track Pilot Reportedly Stalls, a Long-Acting Bispecific for Atopic Dermatitis, and a Twice-Yearly Obesity Approach
FDA has reportedly shelved its Commissioner’s National Priority Voucher pilot and paused publishing complete response letters, Zai Lab’s IL-13/IL-31Rα bispecific ZL-1503 shows a 40- to 50-day half-life that points to dosing every 12 weeks, and Wave Life Sciences reports 1-year INLIGHT data for its INHBE-silencing siRNA WVE-007 in obesity.
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.